Preladenant

DRUG10 trials

Conditions

Akathisia, Drug-InducedAntipsychotic AgentsBrain DiseasesCentral Nervous System DiseasesChronic Hepatic ImpairmentDyskinesia, Drug-InducedIdiopathic Parkinson DiseaseIdiopathic Parkinson's Disease

Phase 1

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

CompletedNCT01323855

Merck Sharp & Dohme LLCParkinson Disease

Start: 2011-03-28End: 2011-11-29Updated: 2018-10-02

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

CompletedNCT01465412

Merck Sharp & Dohme LLCChronic Hepatic Impairment

Start: 2011-11-10End: 2012-06-14Updated: 2018-09-24

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

TerminatedNCT03099161

Merck Sharp & Dohme LLCNeoplasm

Start: 2017-06-27End: 2018-02-21Updated: 2019-06-05

Phase 2

Dyskinesia in Parkinson's Disease (Study P04501)

CompletedNCT00406029

Merck Sharp & Dohme LLCBrain Diseases, Central Nervous System Diseases, Movement Disorders +2

Start: 2006-11-20End: 2008-11-03Updated: 2018-11-09

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

CompletedNCT00537017

Merck Sharp & Dohme LLCBrain Diseases, Central Nervous System Diseases, Movement Disorders +2

Start: 2007-11-23End: 2009-11-19Updated: 2021-02-02

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

TerminatedNCT00686699

Merck Sharp & Dohme LLCAkathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders

Start: 2006-07-10End: 2008-03-06Updated: 2018-11-09

Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)

TerminatedNCT00693472

Merck Sharp & Dohme LLCAkathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders

Start: 2007-08-15End: 2009-01-09Updated: 2018-11-07

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

CompletedNCT01294800

Merck Sharp & Dohme LLCParkinson's Disease

Start: 2011-02-25End: 2013-06-01Updated: 2018-11-08

Phase 3

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

TerminatedNCT01215227

Merck Sharp & Dohme LLCIdiopathic Parkinson Disease, Parkinson Disease

Start: 2010-11-18End: 2013-07-16Updated: 2018-11-06

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

CompletedNCT01227265

Merck Sharp & Dohme LLCIdiopathic Parkinson Disease, Idiopathic Parkinson's Disease, Parkinson Disease

Start: 2010-11-19End: 2013-04-16Updated: 2018-09-24

Related Papers

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease

JAMA Neurology2015-11-0290 citations

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.